Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyCharles J. Ryan, Dana E. Rathkopf, Joan Carles et al.|New England Journal of Medicine|2012Cited by 2.8k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|The Lancet Oncology|2015Cited by 1.4k
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)Dana E. Rathkopf, Fred Saad, Matthew R. Smith et al.|European Urology|2014Cited by 273
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Charles S. Cleeland, Karen A. Autio et al.|The Lancet Oncology|2013Cited by 153
Treatment of advanced ovarian cancer with sequential combination chemotherapyThomas W. Griffin, Mary E. Costanza, RICHARD A. HUNTER et al.|Cancer|1987Cited by 14